PDCD1 and non-small cell lung carcinoma: Accordingly, the present study aimed to evaluate whether the quantitative or qualitative loss of lumbar skeletal muscle is predictive of the efficacy of PD‐1/PD‐L1 inhibitors, regardless of confounding factors, in patients with advanced NSCLC.